575References
Ananthakrishnan AN. Personalizing therapy for infl ammatory bowel diseases. Expert Rev
Gastroenterol Hepatol. 2013;7:549–58.
Camilleri M. Pharmacogenomics and serotonergic agents: research observations and potential
clinical practice implications. Neurogastroenterol Motil. 2007;19(s2):40–5.
Ceriello A, Barkai L, Christiansen JS, et al. Diabetes as a case study of chronic disease management
with a personalized approach: the role of a structured feedback loop. Diabetes Res Clin Pract.
2012;98:5–10.
Cobb JP, Mindrinos MN, Miller-Graziano C, et al. Application of genome-wide expression analy-
sis to human health and disease. Proc Natl Acad Sci U S A. 2005;102:4801–6.
Emami-Riedmaier A, Schaeffeler E, Nies AT, et al. Stratifi ed medicine for the use of anti-diabetic
medication in treatment of type 2 diabetes and cancer: where do we go from here? J Intern
Med. 2014. doi: 10.1111/joim.12330.
Levy-Nissenbaum E, Bar-Natan M, Frydman M, Pras E. Confi rmation of the association between
male pattern baldness and the androgen receptor gene. Eur J Dermatol. 2005;15:339–40.
Mosli MH, Sandborn WJ, Kim RB, et al. Toward a personalized medicine approach to the manage-
ment of infl ammatory bowel disease. Am J Gastroenterol. 2014;109:994–1004.
Nappi RE, Domoney C. Pharmacogenomics and sexuality: a vision. Climacteric. 2013;16(1):
25–30.
Schmidt MA, Goodwin TJ. Personalized medicine in human space fl ight: using omics based analy-
ses to develop individualized countermeasures that enhance astronaut safety and performance.
Metabolomics. 2013;9:1134–56.
Shepard JA, Gonder-Frederick L, Vajda K, Kovatchev B. Patient perspectives on personalized
glucose advisory systems for type 1 diabetes management. Diabetes Technol Ther. 2012;14:
858–61.
Spiegel AM, Hawkins M. ‘Personalized medicine’ to identify genetic risks for type 2 diabetes and
focus prevention: can it fulfi ll its promise? Health Aff (Millwood). 2012;31:43–9.
Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in infl ammatory bowel
disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16:378.
Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis – where do we go from
here? NEJM. 2012;366:2048–51.
References